Lupin jumps on launching Sacubitril and Valsartan Combination Drug for Heart Failure Patients

18 Jan 2023 Evaluate

Lupin is currently trading at Rs. 767.00, up by 13.95 points or 1.85% from its previous closing of Rs. 753.05 on the BSE.

The scrip opened at Rs. 753.00 and has touched a high and low of Rs. 769.70 and Rs. 753.00 respectively. So far 20575 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 969.00 on 19-Jan-2022 and a 52 week low of Rs. 583.05 on 25-May-2022.

Last one week high and low of the scrip stood at Rs. 769.70 and Rs. 745.15 respectively. The current market cap of the company is Rs. 34848.30 crore.

The promoters holding in the company stood at 47.10%, while Institutions and Non-Institutions held 43.36% and 9.53% respectively.

Lupin has launched combination drug Sacubitril and Valsartan under two brand names, Valentas and Arnipin, in India. This drug combination is indicated for patients with Heart Failure (HF) conditions. Valentas and Arnipin tablets are available in 200 mg, 100 mg, and 50 mg. Valentas and Arnipin are indicated to reduce repeated hospitalization and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2097.65 5.70 (0.27%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×